Moreover, these proteases can degrade SMN proteins through either direct binding (e.g., calpain 1/7) or other mechanisms, including lysosomal-mediated pathway (e.g., CTSL/CTSB), providing novel targets for therapeutic interventions for SMA. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.